Rothschild Investment Corp IL trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 26.3% during the fourth quarter, HoldingsChannel reports. The firm owned 14,270 shares of the biopharmaceutical company’s stock after selling 5,084 shares during the quarter. Rothschild Investment Corp IL’s holdings in Gilead Sciences were worth $1,022,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in GILD. Capital International Investors lifted its stake in Gilead Sciences by 86.6% during the third quarter. Capital International Investors now owns 11,217,015 shares of the biopharmaceutical company’s stock worth $908,803,000 after purchasing an additional 5,205,983 shares in the last quarter. Sanders Capital LLC acquired a new stake in shares of Gilead Sciences in the third quarter valued at $427,585,000. Skandinaviska Enskilda Banken AB publ raised its stake in shares of Gilead Sciences by 230.0% in the third quarter. Skandinaviska Enskilda Banken AB publ now owns 4,927,585 shares of the biopharmaceutical company’s stock valued at $399,233,000 after acquiring an additional 3,434,450 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Gilead Sciences by 35.0% in the second quarter. Renaissance Technologies LLC now owns 10,407,848 shares of the biopharmaceutical company’s stock valued at $736,667,000 after acquiring an additional 2,700,600 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its stake in shares of Gilead Sciences by 84.7% in the third quarter. Ameriprise Financial Inc. now owns 5,505,708 shares of the biopharmaceutical company’s stock valued at $446,197,000 after acquiring an additional 2,524,657 shares in the last quarter. Institutional investors own 75.71% of the company’s stock.
Several brokerages have recently issued reports on GILD. Vetr upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.25 price objective on the stock in a research note on Monday, February 5th. Leerink Swann reduced their price objective on Gilead Sciences from $86.00 to $83.00 and set a “market perform” rating on the stock in a research note on Wednesday, February 7th. Citigroup reiterated a “buy” rating and issued a $105.00 price objective (up from $103.00) on shares of Gilead Sciences in a research note on Thursday, February 8th. BMO Capital Markets increased their price objective on Gilead Sciences from $86.00 to $88.00 and gave the company a “market perform” rating in a research note on Thursday, February 8th. Finally, Mizuho increased their price objective on Gilead Sciences from $77.00 to $83.00 and gave the company a “buy” rating in a research note on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the stock. Gilead Sciences has a consensus rating of “Buy” and a consensus target price of $86.92.
Shares of Gilead Sciences, Inc. (GILD) opened at $80.91 on Monday. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $89.54. The company has a quick ratio of 3.48, a current ratio of 3.55 and a debt-to-equity ratio of 1.10. The firm has a market capitalization of $105,690.23, a price-to-earnings ratio of 9.47, a price-to-earnings-growth ratio of -1.85 and a beta of 1.22.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The company had revenue of $5.95 billion for the quarter, compared to analysts’ expectations of $5.71 billion. During the same period last year, the firm earned $2.70 earnings per share. Gilead Sciences’s quarterly revenue was down 18.7% on a year-over-year basis. equities research analysts predict that Gilead Sciences, Inc. will post 6.24 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be issued a dividend of $0.57 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date is Thursday, March 15th. This represents a $2.28 annualized dividend and a dividend yield of 2.82%. Gilead Sciences’s dividend payout ratio (DPR) is presently 59.77%.
COPYRIGHT VIOLATION NOTICE: This report was posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.tickerreport.com/banking-finance/3222839/rothschild-investment-corp-il-decreases-holdings-in-gilead-sciences-inc-gild.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.